ReviewFrontiers in cell and developmental biology2021
Novel Characterization of Myeloid-Derived Suppressor Cells in Tumor Microenvironment.
Review in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Turning off methylglyoxal stress: an alternative approach to inhibit MDSC expansion and metastasis in triple-negative breast cancer.Journal for immunotherapy of cancer · 2026Article
- Exosomal regulation of cellular reprogramming and polarization in the tumor microenvironment.Cancer cell international · 2025Review
- Targeting vascular endothelial growth receptor-2 (VEGFR-2): structural biology, functional insights, and therapeutic resistance.Archives of pharmacal research · 2025Review
- A novel method for isolation of tumor infiltrating myeloid-derived suppressor cells from human lung tumor tissue.Scientific reports · 2025Article
- Article
- Chemoresistance in Pancreatic Cancer: The Role of Adipose-Derived Mesenchymal Stem Cells and Key Resistance Genes.International journal of molecular sciences · 2025Article
- Gene Signature-Based Drug Screening Reveals Ponatinib Enhances Immunotherapy Efficacy in Triple-Negative Breast Cancer by Reversing MDSC-Mediated Immunosuppressive Tumor Microenvironment.Research (Washington, D.C.) · 2025Article
- The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers.Frontiers in immunology · 2025Review
- Epigenetic regulation of the tumor microenvironment in lung cancer: mechanism insights and therapeutic prospects.Frontiers in immunology · 2025Review
- Immune Cell Profiling Reveals a Common Pattern in Premetastatic Niche Formation Across Various Cancer Types.Cancer medicine · 2025Article
- Reduction of myeloid-derived suppressor cells in prostate cancer murine models and patients following white button mushroom treatment.Clinical and translational medicine · 2024Article
- Myeloid-derived suppressor cells promote allograft survival by suppressing regulatory T cell dysfunction in high-risk corneal transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2024Article
- Hallmarks of cancer resistance.iScience · 2024Review
- Tumor-Associated Monocytes Reprogram CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics.Frontiers in immunology · 2024Review
- Unlocking the tumor-immune microenvironment in osteosarcoma: insights into the immune landscape and mechanisms.Frontiers in immunology · 2024Review
- Global trends in tumor microenvironment-related research on tumor vaccine: a review and bibliometric analysis.Frontiers in immunology · 2024Review
- Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance.Cancers · 2023Review
- Modulation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment by Natural Products.Archivum immunologiae et therapiae experimentalis · 2023Review
- Therapies Targeting Immune Cells in Tumor Microenvironment for Non-Small Cell Lung Cancer.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of cells generated in various pathologic conditions, which have been known to be key components of the tumor microenvironment (TME) involving in tumor immune tolerance. So MDSCs have been extensively researched recently. As its name suggests, immunosuppression is the widely accepted function of MDSCs. Aside from suppressing antitumor immune responses, MDSCs in the TME also stimulate tumor angiogenesis and metastasis, thereby promoting tumor growth and development. Therefore, altering the recruitment, expansion, activation, and immunosuppression of MDSCs could partially restore antitumor immunity. So, this view focused on the favorable TME conditions that promote the immunosuppressive effects of MDSCs and contribute to targeted therapies with increased precision for MDSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.